Ironwood Pharmaceuticals is seeking approval from the European Medicines Agency for their Irritable Bowel Syndrome drug Linaclotide.
Almirall is the licensee of Linaclotide for European markets. They along with Linaclotide manufacturer, Ironwood Pharmaceuticals, submitted a Marketing Authorization Application to the European Medicines Agency in a bid to gain access to European markets. Along with the application they submitted the results of their Phase III trials showcasing the benefits they feel Linaclotide provides patients who are dealing with Irritable Bowel Syndrome. If approved the drug would be sold under the brand name of Constella. Continue reading “Ironwood’s Irritable Bowel Syndrome Constipation Drug Seeking European Approval” »